Paul G. Allen Frontiers Group [to 24 Aug 2019]
News from The Paul G. Allen Frontiers Group: August 2019
August 6, 2019
Highlights include a roundup of our recent Exploring Frontiers symposiums on modeling and morphogensis, a funding initiative for new cancer initiatives and more.


BMGF – Gates Foundation [to 24 Aug 2019]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 24 Aug 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 24 Aug 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
08.20.2019  |
CARB-X funds Vaxxilon AG to develop a new vaccine to prevent carbapenem-resistant superbug Klebsiella pneumoniae infections
Multivalent conjugate vaccine aims to prevent deadly hospital-acquired respiratory, urinary-tract and other infections that kill thousands of patients each year
(BOSTON, USA) – CARB-X, a global partnership led by Boston University, is awarding Vaxxilon AG of Reinach, Switzerland, up to $1.4 million in non-dilutive funding with the possibility of $3.1 million more if certain project milestones are met, to develop a multivalent vaccine to prevent infections caused by carbapenem-resistant bacteria Klebsiella pneumoniae, an invasive Gram-negative superbug associated with life-threatening intensive-care and hospital-acquired infections and high mortality rates.
“Vaccines are vital tools in the fight against disease and drug-resistant bacteria, with the potential to prevent infections and reduce the spread of life-threatening bacteria,” said Kevin Outterson, Executive Director of CARB-X and Professor of Law at Boston University. “Vaxxilon’s vaccine, if approved for use in patients, could prevent deadly infections and save the lives of thousands of patients in hospitals worldwide who might otherwise contract infections and die.”…

8.15.2019  |
CARB-X funds Integrated Biotherapeutics to expand the development of its Staphylococcus aureus vaccine to facilitate use in the developing world
CARB-X, a global partnership led by Boston University, is awarding Integrated Biotherapeutics (IBT) of Rockville, Maryland, USA, $1.6 million to expand the development of its vaccine against Staphylococcus aureus, including  Methicillin-resistant Staphylococcus aureus (MRSA) superbugs, so that the vaccine can be used to prevent infections in developing nations, as well as in the developed world. Under this initiative, IBT will expand its R&D to evaluate the efficacy of its vaccine, IBT-V02, against strains of the bacteria found in developing nations, and will also explore development of a freeze-dried version of the vaccine so that it can be used where cold storage systems are not available.


CEPI – Coalition for Epidemic Preparedness Innovations [to 24 Aug 2019]
21 August 2019
CEPI and Africa CDC to host panel event at TICAD 7
How can we strengthen epidemic preparedness and response in Africa?
This is the topic CEPI and the Africa CDC will be exploring on Wednesday, August 28, at the seventh Tokyo International Conference on African Development (TICAD 7).
We will be hosting a high-level panel event to discuss the challenges of epidemic preparedness in Africa and how CEPI, the Africa CDC, and its partners in Africa can and should be working together…


Clinton Health Access Initiative, Inc. (CHAI) [to 24 Aug 2019]
No new digest content identified.


EDCTP [to 24 Aug 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
21 August 2019
Invitation to apply for membership of the EDCTP Audit Committee
The European & Developing Countries Clinical Trials Partnership (EDCTP) invites suitable candidates to apply for membership of its Audit Committee. EDCTP is a public-public partnership of, currently, 16 African and 14 European countries, and the European Union. The Delegation Agreement…

14 August 2019
EC invites feedback on next EDCTP programme
The European Commission seeks feedback from citizens and stakeholders on its outline for an EDCTP successor programme. This is one of the early steps in the process of creating a future EDCTP programme under the umbrella of the next European…


Emory Vaccine Center [to 24 Aug 2019]
No new digest content identified.


European Medicines Agency [to 24 Aug 2019]
News and press releases
News: EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US
Last updated: 16/08/2019


European Vaccine Initiative [to 24 Aug 2019]
No new digest content identified.


FDA [to 24 Aug 2019]
No new digest content identified.


Fondation Merieux [to 24 Aug 2019]
No new digest content identified.


Gavi [to 24 Aug 2019]
Latest news
Using drones to reach remote communities with vaccines in the Democratic Republic of the Congo
09 August 2019
During a recent visit to the Democratic Republic of the Congo (DRC), Gavi spoke to Freddy Nkosi, Senior Manager of Advocacy and Communications at VillageReach, about the planned vaccine delivery drone launch in Équateur Province in the north of the DRC. Nkosi is based in the DRC capital, Kinshasa, and is part of the regional and global VillageReach team


GHIT Fund [to 24 Aug 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.


Global Fund [to 24 Aug 2019]
European Union Announces Major Increase to the Global Fund
24 August 2019
… President of the European Council Donald Tusk announced on behalf of the EU a pledge of €550 million for the Global Fund’s Sixth Replenishment during the G7 Summit in Biarritz. This represents an increase of 16 percent over their previous contribution…

Canada Steps Up Fight Against Epidemics with a Major Increase to Global Fund
22 August 2019
GENEVA – The Global Fund warmly welcomed today’s announcement by Canadian Minister of International Development and Minister for Women and Gender Equality, Maryam Monsef, of a new pledge of CAD 930.4 million to the Global Fund for the next three years. The new pledge – representing a 15.7% increase from Canada’s previous pledge – is a tremendous investment in global efforts to end the epidemics of HIV, TB and malaria…

Switzerland Increases Contribution to Global Fund
21 August 2019
… In its meeting today in Bern, the Swiss Federal Council approved a contribution of CHF64 million to the Global Fund’s Sixth Replenishment. This is the highest contribution ever granted by Switzerland to the Global Fund…

Patricia Moser Elected Chair of Technical Review Panel
20 August 2019
GENEVA − The Technical Review Panel, a group of independent experts who review requests for funding to the Global Fund, has elected Dr. Patricia Moser as its new chair.
Dr. Moser is a distinguished public health economist from the United States, with more than three decades of experience improving access to health services and health outcomes in low- and middle-income countries.
Dr. Moser has worked extensively on efforts to remove HIV, tuberculosis and malaria as major impediments to improved health, and supporting stronger health systems that are an indispensable component of ending epidemics…


Hilleman Laboratories [to 24 Aug 2019]
No new digest content identified.


Human Vaccines Project [to 24 Aug 2019]
Press Release
Four Distinguished Global Leaders Join Efforts to Decode the Human Immune System
New York – August 13, 2019 – Four distinguished global leaders are joining the Human Vaccines Project to help push forward its effort to solve one the greatest public health challenges of the 21st century, the decoding of the human immune system. A 21-year member of Australia’s Parliament who spent five years as Foreign Minister, the Honorable Julie Bishop will join the Board of Directors. Internationally recognized Dutch virologist Jaap Goudsmit takes the helm as Chief Scientific Officer and Senior Vice President, while Soumya Swaminathan of the World Health Organization and Jerome Kim of the International Vaccine Institute join the Project’s Scientific Steering Committee…


IAVI [to 24 Aug 2019]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities (ICMRA)
Statements and Press Releases
No new digest content identified.



No new digest content identified.


IFRC [to 24 Aug 2019]
Selected Press Releases, Announcements
Asia Pacific, Bangladesh, Myanmar
Press release: Rakhine crisis – Two years on, the struggle for safety, privacy and dignity
Tens of thousands of people who fled violence in Rakhine to camps in Cox’s Bazar, Bangladesh are living their lives in cramped tents and shelters, in conditions that fall well below international standards.


IVAC [to 24 Aug 2019]
Four takeaways from iHEA 2019, a Swiss summit on health economics
August 2019
Last month, representatives from the IVAC Economics and Finance (E&F) team attended the International Health Economics Association (iHEA) Congress in Basel, Switzerland. As new members of Immunization Economics, a specialized group of economists working on immunization, Bryan Patenaude, Cristina Garcia, Gatien de Broucker, and Elizabeth (Libby) Watts had several significant contributions to the biannual conference. […]


IVI [to 24 Aug 2019]
IVI News & Announcements
IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System
August 16, 2019 – SEOUL, South Korea – Dr. Jerome Kim, Director General of the International Vaccine Institute (IVI), joins the Human Vaccines Project as one of four distinguished global leaders to help push forward its effort to solve one the greatest public health challenges of the 21st century, the decoding of the human immune system. Dr. Kim will join the Project’s Scientific Steering Committee, together with Dr. Soumya Swaminathan of the World Health Organization.  The Honorable Julie Bishop, a 21-year member of Australia’s Parliament who spent five years as Foreign Minister will join the Project’s Board of Directors and internationally recognized Dutch virologist Jaap Goudsmit takes the helm as Chief Scientific Officer and Senior Vice President….


JEE Alliance [to 24 Aug 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 24 Aug 2019]
Selected News; Project Updates, Reports
A multidisciplinary approach to stem the spread of cholera
Project Update 21 Aug 2019

Rohingya refugee crisis
Two years on: No solutions in sight for the Rohingya
Project Update 20 Aug 2019

Democratic Republic of Congo
A deadly measles outbreak is spreading like wildfire
Project Update 16 Aug 2019

Promising new tuberculosis drug pretomanid approved, but will it be affordable?
Press Release 15 Aug 2019

The struggle of Venezuelan migrants and asylum seekers in northern Brazil
Project Update 14 August 2019


NIH [to 24 Aug 2019]
August 21, 2019
NIH funds genetic counseling resource ahead of million-person sequencing effort
— Genetic counseling and technological infrastructure for the All of Us Research Program to be provided by Color.

August 14, 2019
Leaders of NIH’s All of Us Research Program recap progress and next steps
— Strong progress has been made in efforts to advance precision medicine

Monday, August 12, 2019
Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates
The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) as part of the emergency response to an ongoing Ebola outbreak in the North Kivu and Ituri Provinces.
As of Aug. 9, 2019, the trial had enrolled 681 patients toward an enrollment total of 725. Patients were enrolled at four Ebola Treatment Centers (ETCs) in Beni, Katwa, Butembo and Mangina. These ETCs have been overseen by staff from the Institut National de Recherche Biomédicale (INRB); the DRC Ministry of Health; and three medical humanitarian organizations: the Alliance for International Medical Action (ALIMA), the International Medical Corps (IMC), and Médecins Sans Frontières (MSF).
The trial is monitored by an independent data and safety monitoring board (DSMB) that meets periodically to review interim safety and efficacy data and to make recommendations to the study team and the sponsors. As a result of their Aug. 9, 2019 review, the DSMB recommended that the study be stopped and that all future patients be randomized to receive either REGN-EB3 or mAb114 in what is being considered an extension phase of the study. This recommendation was based on the fact that an early stopping criterion in the protocol had been met by one of the products, REGN-EB3. The preliminary results in 499 study participants indicated that individuals receiving REGN-EB3 or mAb114 had a greater chance of survival compared to participants in the other two arms.
The principal investigators of the study, its statistician and its co-sponsors accepted this recommendation, and the ETC staff at the sites were promptly informed. In addition to limiting future patient randomizations to REGN-EB3 and mAb114, patients who were randomized to ZMapp or remdesivir in the last 10 days now have the option, at the discretion of their treating physician, to receive either REGN-EB3 or mAb114…

August 8, 2019
NIH-funded study will test seasonal flu vaccines with two experimental adjuvants
— Adjuvants are compounds added to vaccines to induce stronger and longer-lasting immune responses


PATH [to 24 Aug 2019]
August 14, 2019 by PATH
In new Living Labs initiative, health care workers will co-create solutions to increase immunization coverage in sub-Saharan Africa
Seattle, WA, August 14, 2019 – PATH and the Bill & Melinda Gates Foundation have launched a new partnership to develop innovative approaches that engage and build on the motivation of frontline immunization workers for improved performance. The Living Labs initiative will put health care workers at the center of defining the challenges they face in their daily work and being the architects of creative solutions. This project is a new way for PATH, the Gates Foundation, and health care workers to partner as co-creators in the rapid designing, prototyping, and testing of new solutions to increase immunization coverage and equity…


Sabin Vaccine Institute [to 24 Aug 2019]
August 13, 2019
Sabin Vaccine Institute Elects New Trustees Bringing Expertise to Support Program Growth
WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) announces the appointment of three new members to its Board of Trustees. Joining the Board are Drs. Elizabeth Fox, Saad Omer and Jacqueline Shea, well-respected leaders whose range of skills and experience promise to advance Sabin’s aim to ensure all people, everywhere get the vaccines they need.

August 6, 2019
GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.


UNAIDS [to 24 Aug 2019]
Selected Press Releases/Reports/Statements
22 August 2019
Osh signs the Paris Declaration
Osh, Kyrgyzstan, has become the latest city to sign the Paris Declaration to end the AIDS epidemic in cities, becoming the second city in the country to commit to reaching the 90–90–90 targets by the end of 2020.

15 August 2019
Preparedness, proactiveness and speed are key to tackling humanitarian emergencies

15 August 2019
Preventing HIV and sexual and gender-based violence in peacekeeping and humanitarian operations

14 August 2019
Redefining HIV prevention messages for young people in Latin America


UNICEF [to 24 Aug 2019]
Selected Statements, Press Releases, Reports
G7 leaders must prioritize children in Syria as violence mounts in the northwest
Statement by UNICEF Executive Director Henrietta Fore

Press release
Venezuela: UNICEF seeks US$70 million to provide humanitarian assistance to 900,000 children
NEW YORK/PANAMA, 20 August 2019 – UNICEF appealed for more than US$70 million to provide life-saving humanitarian assistance to 900,000 children across Venezuela through the end of the year. New funding in the coming weeks is essential for UNICEF and its partners to meet the critical humanitarian needs of children and families inside the country.

“Some 3.2 million children in Venezuela need humanitarian aid as conditions across the country continue to deteriorate,” said UNICEF Executive Director Henrietta Fore. “We are ramping up our work to help children and families who are struggling against food shortages and limited access to essential services like healthcare, safe water and education.”

At least 4.3 million people across Venezuela do not have access to safe drinking water; vaccine-preventable diseases including measles and diphtheria have re-emerged, while yellow fever and malaria are on the rise. An estimated 1.3 million children and adolescents need protection services, while over 1 million children are out of school.

In line with the 2019 Humanitarian Response Plan (HRP) for Venezuela launched by the United Nations and its partners, UNICEF’s priorities for the remainder of the year include:
:: Providing 800,000 people with access to safe drinking water;
:: Continuing to rehabilitate the vaccine cold chain;
:: Vaccinating more than 1,200,000 children under 5 years against measles;
:: Ensuring treatment for 7,000 children under 5 years suffering from severe or moderate malnutrition;
:: Distributing education materials to 680,000 children aged 4-18 years;
:: Reaching 216,000 children with psychosocial and protection support; and
:: Providing over 170,000 pregnant women and newborn babies with health assistance.

These efforts build on UNICEF’s existing programmatic reach which has increased steadily over the past year to meet the growing needs of the most vulnerable children. Since 2018, UNICEF has shipped nearly 200 tons of basic health, nutrition, education, water and sanitation relief supplies to Venezuela…

Press release
Number of children orphaned or left unaccompanied by Ebola in the Democratic Republic of the Congo rising fast

Press release
UNICEF welcomes Government of Colombia decision to prevent statelessness for thousands of children born in Colombia to Venezuelan parents


Vaccination Acceptance Research Network (VARN) [to 24 Aug 2019]
No new digest content identified.


Vaccine Confidence Project [to 24 Aug 2019]
No new digest content identified.


Vaccine Education Center – Children’s Hospital of Philadelphia [to 24 Aug 2019]
No new digest content identified.


Wellcome Trust [to 24 Aug 2019]
News | 23 August 2019
Four new appointments to Wellcome’s Board of Governors
Four leaders with significant experience across the finance, advertising, NGO and banking sectors have been appointed to our Board of Governors.

Opinion | 13 August 2019
The most important healthcare tool is trust
by Jeremy Farrar
Wellcome Global Monitor shows that 70% of people trust scientists, doctors, and nurses.

Opinion | 5 August 2019
Asking better questions: how we’re using the discovery process in public engagement
Haidee Bell, Strategic Design and Innovation Lead Wellcome
Discovery can be a useful process to start thinking about how, when and why a challenge should be approached. Haidee Bell explains how we’re using discovery to understand opportunities for public engagement in areas as diverse as mental health research and online health information.


The Wistar Institute [to 24 Aug 2019]
Press Release
Aug. 21, 2019
Repeated Semen Exposure Promotes Host Resistance to Infection in Preclinical Model of HIV
Changes in systemic and local tissue responses reduce susceptibility but do not block infection.


World Organisation for Animal Health (OIE) [to 24 Aug 2019]
No new digest content identified.





BIO [to 24 Aug 2019]
No new digest content identified.


DCVMN – Developing Country Vaccine Manufacturers Network [to 24 Aug 2019]
No new digest content identified.


IFPMA [to 24 Aug 2019]
Selected Press Releases, Statements, Publications
22 August 2019
IFPMA Statement on WHO Afro 69 agenda item 12 Framework for provision of essential health
… IFPMA believes that structured, collaborative action on UHC is needed to meet the shared goals of expanding patient access to medicines through innovative solutions, and achieving long-term sustainability of the health sector. This is all the more necessary given the complex mix of interconnected threats to global health which we increasingly face —from poverty and pandemics to conflict and environmental issues.
In the run-up to the UN High Level Meeting in September and as a Core Member of the Private Sector Constituency of UHC 2030, we are pleased to see the Key Asks from the UHC movement going in the right direction. We support in particular the need to uphold quality primary health care, drive forward sustainable financing, and provide an enabling environment to promote improved access to medicines and vaccines, facilitating continued innovation to find new treatments and cures that ensure no-one is left behind.
Now is the time to take action and step forward together in expanding quality, essential health coverage – and to see it not as a cost but as a genuine investment in our human capital, as the drivers of economic development and growth. The opportunities are great in the AFRO region, particularly given the demographic dividend, and we look forward to continuing a constructive and inclusive debate on how to help countries move forward on achieving UHC.


PhRMA [to 24 Aug 2019]
No new digest content identified.


Industry Watch [to 24 Aug 2019]
:: Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina
August 21, 2019
NEW YORK–(BUSINESS WIRE)–Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support Pfizer’s continuing investment in gene therapy research and development, similar to Pfizer’s Chapel Hill and Kit Creek, North Carolina research and development sites. This facility would expand the company’s presence in North Carolina, where there are currently more than 3,600 Pfizer colleagues, including 650 in Sanford. The expanded facility is projected to add approximately 300 new jobs…